Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Ezra Friedberg Sells 558 Shares

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Ezra Friedberg sold 558 shares of Pelthos Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $20.92, for a total transaction of $11,673.36. Following the transaction, the director owned 82,027 shares of the company’s stock, valued at $1,716,004.84. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Stock Up 19.5%

Shares of PTHS opened at $24.38 on Tuesday. The company has a market capitalization of $81.92 million, a P/E ratio of -1.17 and a beta of 3.93. The company has a quick ratio of 1.15, a current ratio of 2.05 and a debt-to-equity ratio of 0.81. The firm’s 50 day moving average price is $22.86. Pelthos Therapeutics Inc. has a twelve month low of $9.00 and a twelve month high of $54.29.

Institutional Investors Weigh In On Pelthos Therapeutics

A number of large investors have recently added to or reduced their stakes in PTHS. Ikarian Capital LLC grew its position in Pelthos Therapeutics by 309.5% in the 4th quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock worth $7,928,000 after purchasing an additional 193,307 shares during the period. J. Goldman & Co LP bought a new stake in Pelthos Therapeutics in the 4th quarter worth approximately $2,418,000. Boothbay Fund Management LLC grew its position in Pelthos Therapeutics by 279.8% in the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after purchasing an additional 59,435 shares during the period. Cantor Fitzgerald L. P. bought a new stake in Pelthos Therapeutics in the 4th quarter worth approximately $1,085,000. Finally, Diadema Partners LP grew its position in Pelthos Therapeutics by 138.1% in the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after purchasing an additional 14,502 shares during the period. Institutional investors own 77.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on PTHS. Zacks Research raised shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Piper Sandler began coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They set an “overweight” rating and a $48.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Cantor Fitzgerald began coverage on shares of Pelthos Therapeutics in a research report on Wednesday, April 1st. They set an “overweight” rating and a $50.00 price target for the company. Finally, Roth Mkm reduced their price target on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $55.00.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).